Summit signs licensing deal worth up to $5bn for Akeso’s ivonescimab
Summit Therapeutics has signed a licensing deal worth up to $5bn with Chinese biopharma firm Akeso for the latter’s ivonescimab, a bispecific antibody candidate for cancer. Ivonescimab is